Frazier Life Sciences VIII, L.P. 3
3 · Entasis Therapeutics Holdings Inc. · Filed Sep 25, 2018
Insider Transaction Report
Form 3
Frazier Life Sciences VIII, L.P.
10% Owner
Holdings
Series B-1 Tranche B Convertible Preferred Stock
→ Common Stock (6,651,574 underlying)Series B-1 Tranche A Convertible Preferred Stock
→ Common Stock (5,212,833 underlying)Series B Convertible Preferred Stock
→ Common Stock (7,000,000 underlying)
Footnotes (2)
- [F1]Each share of Series B Convertible Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock is convertible at any time, at the option of the holder, into Common Stock, on a 20.728-for-one basis, has no expiration date and will convert into shares of Common Stock upon the closing of the Issuer's initial public offering.
- [F2]The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any.